Trump’s Tariffs on Medicines From Europe Stand to Cost Drugmakers Billions

Think you know your heart attack risk? A simple scan called a coronary artery calcium test might give you—and your doctor—a clearer picture than traditional checks like cholesterol levels. Some heart specialists argue this tool isn’t used enough, even though it spots hidden plaque buildup that could signal big trouble ahead.

Editor’s Note: Heart disease is sneaky—it doesn’t always show up in routine tests. This scan could be a game-changer for catching risks early, but it’s flying under the radar. If more people knew about it, we might save lives by spotting silent threats before they turn into emergencies.

The FDA is cracking down on sketchy gas station products that mimic opioids. They’ve asked the Justice Department to ban 7-OH, a compound found in unregulated tablets, gummies, and drink mixes that can get you high like painkillers. These products are easy to find but totally unchecked—and now the feds want them off shelves.

Editor’s Note: This isn’t just about some random pills—it’s about shady, accessible products slipping through regulatory cracks. These items are marketed as harmless but pack opioid-like risks, and the FDA’s move signals a growing worry about unregulated substances creeping into everyday stores. If you’ve seen those "legal high" snacks at the counter, they might not be legal for long.

Novo Nordisk is cutting its sales forecasts for its popular weight-loss drug Wegovy, and it’s pointing the finger at compounding pharmacies—smaller operations that mix their own versions of the drug. These knockoffs are eating into Wegovy’s profits, and the company is scrambling to shut them down.

Editor’s Note: This isn’t just about one drugmaker’s bottom line—it’s a sign of how messy the weight-loss drug boom has gotten. With demand sky-high and supply tight, compounding pharmacies are filling the gap with cheaper alternatives, but Novo Nordisk (and likely other pharma giants) isn’t happy about it. The fight over who gets to profit from these blockbuster drugs could shape how patients access them—and how much they cost.

NFL legend Deion Sanders' unexpected bladder cancer diagnosis is sparking urgent conversations about early testing—particularly in Black communities, where disparities in healthcare often delay detection. His public revelation puts a spotlight on a disease that doesn’t always get enough attention, reminding people that catching it early can be lifesaving.

Editor’s Note: When a high-profile figure like Sanders shares a personal health struggle, it cuts through the noise. Bladder cancer is often overlooked in public health discussions, yet it hits Black Americans harder due to systemic gaps in care. His story isn’t just about awareness—it’s a push to close those gaps before more lives are affected.

UnitedHealth, one of the biggest players in the U.S. healthcare industry, just reported a drop in profits—and it’s largely because they’re shelling out more money to cover the rising costs of medical care. This isn’t just a blip; it’s a trend hitting their entire operation, from insurance to clinics.

Editor’s Note: When a giant like UnitedHealth feels the pinch, it’s a sign that the healthcare system’s financial strain isn’t easing up. For everyday folks, this could mean higher premiums or tighter coverage down the line—because if insurers are paying more, they’ll likely pass those costs along. It’s a reminder that the debate over healthcare affordability isn’t going away.